This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
OPTN/UNOS Board of Directors meeting highlights
AST
The OPTN/UNOS Board of Directors met Nov. 12-13 in St. Louis. The Board took action on a number of items, including living donor evaluation and consent, potential donor disease transmission risk, and VCA membership requirements. An executive summary listing all Board actions is available here.
|
|
Share this article:
    |
|
Treatment of AMR in Thoracic Transplants: Free webinar Jan. 20
AST
Explore the diagnosis and treatment strategies, including the role of desensitization, in lung and heart transplantation. Discuss challenges and avenues for further research and investigation. Register today at www.myAST.org/T3.
AST offers 10+ webinars on demand - all free for AST members and only $25 per webinar for non-members. View archives and register for upcoming live webinars at www.myAST.org/T3.
|
UPCOMING EVENTS IN TRANSPLANTATION
|
Discounted early registration & hotel rates for a limited time only
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona
CEOT 2015 is fast approaching, and for a limited time you can save on registration and housing with special discounted promotions. Attend CEOT with a colleague and take advantage of the “Buy One, Get One Half Off” registration through Jan. 25. Going solo? Early registration discounted rates are in effect from now until Jan. 23.
Book your hotel stay at the Sheraton Wild Horse Pass by Jan. 12 to guarantee the discounted rate of $211 per night. Join nearly 300 of your colleagues at this high-energy, interactive meeting to explore how we, as a community involved in transplantation, will move the field forward.
This year’s CEOT will explore some of the following critical challenges:
- How can you participate in the future of new drug development?
- How do we pioneer the repositioning of existing and new drugs?
- How can AST champion the necessary change that affords your patients better outcomes?
Click here to register for CEOT at a discount. Or, learn more about this engaging meeting and view the full program.
PRODUCT SHOWCASE
 |
|
You care about your transplant
patients. And so do we. That’s
why we’re introducing Astellas
Cares—a new program that
offers you customized tools,
educational resources, and
comprehensive support to help
your patients care for their
health. To register, visit
AstellasCares.com/Transplant
today.
|
|
AAI Accepting Abstracts for Immunology 2015TM
AST
Abstracts will be accepted until Jan. 12, 2015, visit the AAI website for complete details. Immunology 2015TM takes place May 8-12, 2015 in New Orleans, Louisiana.
Register for Immunology 2015TM and attend the AST Guest Symposium entitled "T Cell Trafficking during Alloimmunity and Tolerance," taking place May 9. Registration fees increase on March 24.
|
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
Sirolimus use and cancer incidence among US kidney transplant recipients
American Journal of Transplantation
Sirolimus has anti-carcinogenic properties and can be included in maintenance immunosuppressive therapy following kidney transplantation. We investigated sirolimus effects on cancer incidence among kidney recipients. The US transplant registry was linked with 15 population-based cancer registries and national pharmacy claims. Recipients contributed sirolimus-exposed time when sirolimus claims were filled, and unexposed time when other immunosuppressant claims were filled without sirolimus. Cox regression was used to estimate associations with overall and specific cancer incidence, excluding nonmelanoma skin cancers (not captured in cancer registries).
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
Usability testing of the Internet program: 'Teens Taking Charge: Managing My Transplant Online'
Pediatric Transplantation
Adolescents with SOT demonstrate high rates of medication non-adherence and higher rates of graft loss compared to all other age groups. Self-management interventions encompass information-based material designed to achieve disease-related learning and changes in the participant's knowledge and skill acquisition, while providing social support. These interventions have had some success in chronic disease populations by reducing symptoms and promoting self-efficacy and empowerment. Using findings from a needs assessment, an Internet-based self-management program, Teens Taking Charge: Managing My Transplant Online, for youth with SOT was developed.
Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients
Pediatric Transplantation
Children who have undergone SOT mount a lower immune response after vaccination with TIV compared to healthy controls. HD or SD TIV in pediatric SOT was given to subjects 3–17 year and at least six months post-transplant. Subjects were randomized 2:1 to receive either the HD (60 μg) or the SD (15 μg) TIV. Local and systemic reactions were solicited after each vaccination, and immune responses were measured before and after each vaccination.
Hypothermic machine preservation facilitates successful transplantation of 'orphan' extended criteria donor livers
American Journal of Transplantation
Hypothermic machine preservation (HMP) remains investigational in clinical liver transplantation. It is widely used to preserve kidneys for transplantation with improved results over static cold storage (SCS). At our center, we have used HMP in 31 adults receiving extended criteria donor (ECD) livers declined by the originating United Network for Organ Sharing region (“orphan livers”). These cases were compared to ECD SCS cases in a matched cohort study design.
The safety of hand-assisted laparoscopic living donor nephrectomy: The Ohio State University experience with 1500 cases
Clinical Transplantation
Hand assisted laparoscopic donor nephrectomy (HALD) has been performed at our institution since December, 1999. Through May 2014, a total of 1500 HALD procedures have been performed. We have evaluated the outcomes of HALD. The HALD procedure consists of a hand port incision as well as two 12-mm ports. Mean donor age was 40.8 ± 10.8 years, BMI was 27.9 ± 5.0, and there were 541 males, 1271 Caucasians and the left kidney was removed in 1236 patients. All procedures were successfully completed.
Through a glass darkly: Seeking clarity in preventing late kidney transplant failure
Journal of the American Society of Nephrology
A common lament is that long-term kidney transplant outcomes remain the same despite improvements in early graft survival. To be fair, progress has been made—in both our understanding of chronic injury and modestly, graft survival. However, we are still a long way from actually solving this important and difficult problem. In this review, we outline recent data supporting the existence of several causes of renal allograft loss, the incidences of which peak at different time points after transplantation.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
